Article
Chemistry, Medicinal
Yuqing Shen, Yuqi Zhu, Li Zhang, Jiayi Sun, Bo Xie, Hongyan Zhang, Xiuzu Song
Summary: The mechanism of minoxidil in treating androgenetic alopecia (AGA) was investigated through network pharmacology. The results identified that minoxidil targets not only androgenic receptors (AR) but also two new targets, steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) and aromatase (CYP19A1). Further experiments revealed that minoxidil inhibits AR and CYP17A1 expression, increases CYP19A1 activity, reduces dihydrotestosterone formation and binding, and enhances estradiol production, thus treating AGA.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Dermatology
Bevin Bhoyrul, Leila Asfour, Gerhard Lutz, Lorne Mitchell, Rebekka Jerjen, Rodney D. Sinclair, Susan Holmes, Iskander H. Chaudhry, Matthew J. Harries
Summary: This case series analyzed the clinicopathologic characteristics and treatment response of patients with persistent chemotherapy-induced alopecia (pCIA) after breast cancer chemotherapy. Most patients with pCIA had diffuse nonscarring alopecia, female pattern hair loss, or male pattern hair loss, with taxane-containing regimens associated with more severe alopecia. Topical or systemic treatments, including minoxidil, showed improvement in hair density for a significant proportion of patients, indicating potential reversibility of pCIA.
Review
Dermatology
Jay D. Modha, Yashdeep Singh Pathania
Summary: Oral minoxidil has played an important role in the treatment of different types of alopecia with minimal side effects and significant results. It is mainly used for androgenetic alopecia and female pattern hair loss, providing hope and addressing certain issues for patients.
JOURNAL OF COSMETIC DERMATOLOGY
(2022)
Article
Dermatology
Eleni Chovarda, Eleni Sotiriou, Elizabeth Lazaridou, Efstratios Vakirlis, Demetrios Ioannides
Summary: The study found that in patients with AGA, levels of PGD(2) and prostacyclin or PGI(2) were increased in bald areas, while PGE(2) and PGF(2α) levels were decreased in bald areas compared to haired areas. The results suggest a delicate balance between the four proteins in scalp hair follicles, which may be crucial for hair growth maintenance. Additionally, their receptors could be potential targets for AGA treatment.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Dalia Mahmoud Toma, Rabie Bedir Atallah, Ramadan Mohamed Eldahshan
Summary: This study evaluated the efficacy of 1% methotrexate gel and 5% minoxidil gel in treating localized alopecia areata (AA). The results showed no significant difference between the two treatments based on clinical and dermoscopic examination, indicating that both topical methotrexate gel and topical minoxidil gel are effective in treating localized AA.
DERMATOLOGIC THERAPY
(2022)
Article
Pharmacology & Pharmacy
Ying Sun, Yongxiang Zhang, Xiaxia Liu, Yan Tingting, Liyan Shen, Dan Ye, Xia Kong, Yonghui Su, Qingping Tian
Summary: Efforts were made to improve the drug content and entrapment efficiency of minoxidil in transfersomes for effective treatment of alopecia. The optimized transfersomes and its gel exhibited better transdermal penetration ability and hair growth-promoting capacity, making them a promising strategy for the topical treatment of alopecia.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2023)
Article
Biophysics
Priya Mishra, Mayank Handa, Rewati R. Ujjwal, Vanshikha Singh, Prashant Kesharwani, Rahul Shukla
Summary: This review highlights the role of nanotechnology-based drug delivery in the management of alopecia, emphasizing that nanoparticulate-based delivery can enhance the permeability properties of drugs and have better efficacy compared to conventional methods. The etiology of alopecia is diverse, related to lifestyle, genetics, and autoimmune events.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2021)
Article
Surgery
Ratchathorn Panchaprateep
Summary: Androgenetic alopecia is a common type of hair loss caused by genetic factors and systemic androgens. Standard medical treatments include medication and hair transplantation, but some patients do not respond well. Therefore, new treatments have been developed.
FACIAL PLASTIC SURGERY
(2023)
Article
Dermatology
Nathalie Y. Ly, Sophia Fruechte, Maria K. Hordinsky, Neil Sadick, Suleima Arruda, Ronda S. Farah
Summary: Novel androgenetic alopecia treatments include low-dose oral minoxidil, spironolactone, finasteride, and nutritional supplements. Technological advancements in minimally invasive procedures include photobiomodulation and platelet-rich plasma. Hair transplantation techniques such as follicular unit extraction and robotics are now available to clinicians.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Dermatology
A. Villani, G. Fabbrocini, J. Ocampo-Candiani, A. Ruggiero, S. S. Ocampo-Garza
Summary: Oral minoxidil has been proven as a successful and well-tolerated alternative for treating hair loss, including various hair disorders. Further larger randomized studies are needed to determine the optimal treatment protocol and dosage.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Mahmoud Abd El-Rahim Abdallah, Rasha Shareef, Marwa Y. Soltan
Summary: This study assessed the efficacy of intradermal injection of minoxidil 5% for the treatment of patchy non-severe alopecia areata. The results showed that this method had limited efficacy but could speed up recovery.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Medicine, General & Internal
Peter R. Feldman, Pietro Gentile, Charles Piwko, Hendrik M. Motswaledi, Samantha Gorun, Jacob Pesachov, Michael Markel, Maxwell I. Silver, Megan Brenkel, Oriel J. Feldman, Corey L. Kamen, Elizabeth Uleryk, Jaime Guevara-Aguirre, Klaus M. Fiebig
Summary: This study compared the relative efficacy of treatments for androgenetic alopecia (AGA) in men and women. The results showed that most treatments can improve hair density, but Finasteride, 2% Minoxidil, and Viviscal in men were not significantly different from the placebo group. Low-level laser comb, ALRV5XR, and Nutrafol showed better efficacy in both women and men.
FRONTIERS IN MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Peixin Li, Yanfang Sun, Lei Nie, Amin Shavandi, Khaydar E. Yunusov, Yinjian Hua, Guohua Jiang
Summary: Androgenetic alopecia (AGA) is a widespread disease with a higher prevalence among young individuals, and current treatments often cause severe side-effects. In this study, a composite paste system was developed to treat AGA, which combined minoxidil-loaded nanoparticles, valproic acid, and roller-microneedles. The system successfully promoted hair regeneration in AGA mouse model by enhancing perifollicular vascularization and activating hair follicle stem cells. This approach offers benefits such as avoiding liver's first-pass effect, reducing infection risk, and decreasing side effects compared to traditional treatments.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Review
Oncology
Tongyu C. Wikramanayake, Nicole I. Haberland, Aysun Akhundlu, Andrea Laboy Nieves, Mariya Miteva
Summary: Millions of cancer patients receive chemotherapy each year, and around 65% of them experience chemotherapy-induced alopecia (CIA), which is considered one of the most distressing side effects. Scalp cooling is currently the only FDA-approved method to prevent CIA, but its high costs and limited availability hinder its widespread use. This article reviews current options for CIA prevention and treatment, as well as new approaches being tested.
Article
Dermatology
Barbara Pontes Cerqueira Uzel, Gustavo Henrique Soares Takano, Juliana Cabral Nunes Chartuni, Mariana Vicente Cesetti, Camila Fatima Biancardi Gavioli, Andre Moreira Lemes, Izelda Maria Carvalho Costa
Summary: Intradermal injections with 0.5% minoxidil were more effective than placebo in treating female androgenetic alopecia, leading to a significant increase in terminal-to-vellus hair ratio and anagen hairs, as well as improvement in hair loss and volume.
DERMATOLOGIC THERAPY
(2021)